GlassScriptPhysician profile
Benjamin J George
NPI 1811968225
$432,538.84
in general payments reported to CMS, 2019-2025
42 companies · $42K in 2025
The $42K reported for 2025 was more than what 94% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,481 · 2020: $14K · 2021: $59K · 2022: $117K · 2023: $111K · 2024: $86K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $186K · Travel and Lodging: $26K · Consulting Fee: $25K · Food and Beverage: $2,540 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $185,883.00 |
| Travel and Lodging | $26,227.95 |
| Consulting Fee | $25,013.00 |
| Food and Beverage | $2,539.93 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $380,015.14 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $14,375.91 | 2020-2025 | Tagrisso, Calquence |
| Tg Therapeutics, INC. | $12,944.14 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $9,435.00 | 2021-2024 | Imbruvica, Talvey |
| Celgene Corporation | $3,915.58 | 2022-2023 | Pomalyst |
| Glaxosmithkline, LLC. | $2,750.00 | 2021 | |
| Karyopharm Therapeutics INC. | $2,250.00 | 2021 | |
| Bristol Myers Squibb Company | $1,650.00 | 2023 | |
| Seagen INC. | $1,474.95 | 2021 | |
| Taiho Oncology, INC. | $1,250.00 | 2019 | |
| Janssen Biotech, INC. | $1,090.11 | 2019-2025 | Carvykti, Tecvayli, Talvey |
| Amgen INC. | $143.41 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $138.72 | 2019-2022 | |
| Genmab U.S., INC. | $122.53 | 2023 | Epkinly |
| Pfizer INC. | $116.01 | 2019-2025 |
Show all 39 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.